Skip to main content
. Author manuscript; available in PMC: 2018 Jul 16.
Published in final edited form as: Eur J Neurosci. 2016 Jan;43(2):194–203. doi: 10.1111/ejn.13146

Fig. 4.

Fig. 4

An RGD peptide integrin antagonist reduces the N-methyl-D-aspartate (NMDA)-stimulated calcium response in SKF81297-treated striatal slices. The treatment timeline is shown in (a), cumulative percentage plots are shown in (b), and area under the curve data in (c) (vehicle n = 554 cells from 11 fields; SKF81297 n = 476 cells from 11 fields; RGDS n = 673 cells from 14 fields; and RGDS + SKF81297 n = 603 cells from 14 fields). Ordinary one-way ANOVA showed a statistically significant difference across all groups (F3,2301 = 87.27, P < 0.0001). Post hoc testing with Tukey’s method revealed statistically significant differences between vehicle and SKF81297 (q2301 = 15.22, *P < 0.0001), and between SKF81297 and RGD + SKF81297 (q2301 = 19.95, *P < 0.0001). The difference between RGD and RGD + SKF81297 is not significant (q2301 = 0.1468, P > 0.05). Data were derived from vehicle and treated slices from each of three separate mice.